Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 230 across all filing types
Latest filing 2026-01-27 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants
Regulatory Filings Classification · 95% confidence The document is a corporate announcement regarding the positive safety results of a Phase 2 clinical trial (ENACT). Crucially, it states that this specific safety milestone triggers the potential exercise of warrants issued in a previous private placement. Because the primary purpose of the announcement is to inform the market about the triggering of these financial instruments (warrants) and the subsequent capital structure implications, it falls under the category of Capital/Financing Update.
2026-01-27 English
EXACT Therapeutics’ Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium
Regulatory Filings Classification · 95% confidence The document is a short announcement (1700 characters) regarding a company's upcoming presentation of clinical trial data at a medical symposium. It does not contain the full financial report, audit, or proxy materials. As it is a general corporate announcement regarding company activities that does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2026-01-08 English
EXACT Therapeutics to present company update - Attachment: 251125 Exact Therapeutics - DNB Healthcare conf - non-conf.pdf
Investor Presentation Classification · 100% confidence The document is a slide deck presentation titled 'DNB Carnegie Nordic Healthcare Conference 25 November, 2025' for EXACT Therapeutics AS. It contains detailed information about the company's technology (Acoustic Cluster Therapy), clinical trial results (Phase 1 and Phase 2), pipeline, and strategic focus. It is clearly designed for an investor audience, as evidenced by the 'Important notice and disclaimer' section, the focus on market position, and the contact information for the CEO and CBO. It fits the definition of an Investor Presentation (IP).
2025-11-25 English
EXACT Therapeutics to present company update
Report Publication Announcement Classification · 100% confidence The document is a short announcement (947 characters) stating that the company will be presenting at a conference and that the presentation is attached. Per the 'Menu vs Meal' rule, an announcement stating that a report or presentation is attached or available for download is classified as a Report Publication Announcement (RPA).
2025-11-25 English
EXACT Therapeutics AS: New option program and receipt of share options by primary insiders - Attachment: EXTX PDMR attachments to stock announcement.pdf
Director's Dealing Classification · 100% confidence The document is a standard regulatory notification form detailing transactions by persons discharging managerial responsibilities (PDMRs), specifically the CEO, CMO, and CFO of Exact Therapeutics AS. It lists the nature of the transaction (receipt of share options), the names of the individuals, their positions, and the details of the financial instruments. This format is characteristic of a Director's Dealing (DIRS) filing, which reports insider transactions or share-related compensation for executives.
2025-11-24 English
EXACT Therapeutics AS: New option program and receipt of share options by primary insiders
Remuneration Information Classification · 100% confidence The document announces the introduction of a new share option program and the receipt of share options by primary insiders. This falls under the category of director and executive share-related transactions and incentive programs, which is specifically covered by the 'Director's Dealing' (DIRS) category as it involves primary insiders receiving options.
2025-11-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.